Business
Zero Candida Technologies Reports Financial Results for Three and Six Months Ended June 30, 2025 and Provides Business Update
Zero Candida Technologies Reports Financial Results for Three and Six Months Ended June 30, 2025 ...
About this update from Zero Candida Technologies Inc.
[{"type":"text","content":"\n\n\n\n Zero Candida Technologies Reports Financial Results for Three and Six Months Ended June 30, 2025 and Provides Business Update\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n VANCOUVER, BC\n \n\n ,\n \n\n Sept. 3, 2025\n \n\n /CNW/ --\n \n Zero Candida Technologies, Inc.\n \n (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the \"Company\" or \"ZCT\"), a Femtech company developing a SMART, AI-driven medical device to transform women's gynecological health, today announced its financial and operating results for the three and six months ended\n \n June 30, 2025\n \n . All results are reported in Canadian dollars and prepared in accordance with International Financial Reporting Standards (IFRS). The full financial statements and Management's Discussion and Analysis (\"MD&A\") are available on SEDAR+ at\n \n www.sedarplus.ca\n \n .\n \n\n\n\n\n\n\n\n\n \"Q2 has been an important quarter for advancing our device toward human use and laying the foundation for our regulatory and clinical strategy,\" said Eli Ben-Haroosh, Chairman & CEO of Zero Candida Technologies. \"Our discussions with leading hospitals and U.S. pharmaceutical companies this past quarter reinforce both the clinical need and commercial potential of our technology. With regulators and policymakers calling for safer, less drug-reliant healthcare therapies that are cost-effective for patients, we are confident in our ability to deliver a solution for the hundreds of millions of women affected by VVC worldwide.\"\n \n\n\n Business Update\n \n\n\n\n Device Progress:\n \n Advanced device validation and design refinements during the quarter.\n \n\n\n Regulatory Pathway\n \n : Continued documentation and planning to support the Company's anticipated De Novo FDA pathway, as well as B2B and B2C strategies.\n \n\n\n Partner Validation:\n \n Ongoing discussions with major U.S. hospitals and pharmaceutical companies reinforce clinical and commercial demand.\n \n\n\n Macro Environment:\n \n Global regulators are tightening oversight on chemical-based health products, while health ...